Delving into the Latest Updates on Nicotinamide riboside/Pterostilbene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BASIS

Target

NAD+ x SIRT5

Mechanism

NAD+ modulators(NAD(Nicotinamide adenine dinucleotide) modulators), SIRT5 inhibitors(NAD-dependent protein deacetylase sirtuin-5 inhibitors)

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

Aortic AneurysmAcute Kidney Injury

Inactive Indication

Amyotrophic Lateral SclerosisMenopausal syndrome

Originator Organization

Elysium Health, Inc.Startup

Active Organization

Elysium Health, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC16H16O3

InChIKeyVLEUZFDZJKSGMX-ONEGZZNKSA-N

CAS Registry537-42-8

View All Structures (2)

This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year.

Start Date01 Jan 2023

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

NCT04841499 / CompletedNot ApplicableIIT

Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

The purpose of this study is to determine whether a short supplementation (7days) with BASIS™ increases the natural production of estradiol, measured in urinary waste. The overall objective is to determine whether through increased estradiol levels, the undesirable menopausal effects, assessed via questionnaires, are mitigated by a short-term supplementation with BASIS™

Start Date05 Apr 2021

Sponsor / Collaborator

University of South Alabama

[+1]

100 Clinical Results associated with Nicotinamide riboside/Pterostilbene

Login to view more data

100 Translational Medicine associated with Nicotinamide riboside/Pterostilbene

Login to view more data

100 Patents (Medical) associated with Nicotinamide riboside/Pterostilbene

Login to view more data

2

Literatures (Medical) associated with Nicotinamide riboside/Pterostilbene

10 Oct 2022·Human Molecular Genetics

Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301

Article

Author: Dellinger, Ryan W ; Casalena, Gabriella ; Fels, Jasmine A ; Konrad, Csaba ; Manfredi, Giovanni ; Holmes, Holly E

AbstractMetabolic alterations shared between the nervous system and skin fibroblasts have emerged in amyotrophic lateral sclerosis (ALS). Recently, we found that a subgroup of sporadic ALS (sALS) fibroblasts (sALS1) is characterized by metabolic profiles distinct from other sALS cases (sALS2) and controls, suggesting that metabolic therapies could be effective in sALS. The metabolic modulators nicotinamide riboside and pterostilbene (EH301) are under clinical development for the treatment of ALS. Here, we studied the transcriptome and metabolome of sALS cells to understand the molecular bases of sALS metabotypes and the impact of EH301. Metabolomics and transcriptomics were investigated at baseline and after EH301 treatment. Moreover, weighted gene coexpression network analysis (WGCNA) was used to investigate the association of the metabolic and clinical features. We found that the sALS1 transcriptome is distinct from sALS2 and that EH301 modifies gene expression differently in sALS1, sALS2 and the controls. Furthermore, EH301 had strong protective effects against metabolic stress, an effect linked to the antiinflammatory and antioxidant pathways. WGCNA revealed that the ALS functional rating scale and metabotypes are associated with gene modules enriched for the cell cycle, immunity, autophagy and metabolic genes, which are modified by EH301. The meta-analysis of publicly available transcriptomic data from induced motor neurons by Answer ALS confirmed the functional associations of genes correlated with disease traits. A subset of genes differentially expressed in sALS fibroblasts was used in a machine learning model to predict disease progression. In conclusion, multiomic analyses highlighted the differential metabolic and transcriptomic profiles in patient-derived fibroblast sALS, which translate into differential responses to the investigational drug EH301.

02 Jan 2019·Amyotrophic Lateral Sclerosis and Frontotemporal DegenerationQ4 · MEDICINE

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

Q4 · MEDICINE

Article

Author: Obrador, Elena ; Forner, Alfonso ; Pascual, Raquel ; Platero, JosÉ L. ; Guarente, Leonard ; JuÁrez, Marta ; Cuerda-Ballester, María ; de Bernardo, Nieves ; Dellinger, Ryan W. ; Drehmer, Eraci ; AlarcÓn, Jorge ; Fuente, Cristian ; Salvador, Rosario ; Benlloch, MarÍa ; Marchio, Patricia ; Sancho-Castillo, Sandra ; Villaron-Casales, Carlos ; Holmes, Holly E. ; Estrela, José M. ; de la Rubia, JosÉ E. ; Carrera, Sandra ; Sancho, David ; Caplliure-Llopis, Jordi ; GarcÍa-Pardo, Pilar ; Barrios, Carlos

BACKGROUNDAmyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, characterized by progressive loss of spinal and cortical motor neurons, leading to muscular atrophy, respiratory failure, and ultimately death. There is no known cure, and the clinical benefit of the two drugs approved to treat ALS remains unclear. Novel disease-modifying therapeutics that are able to modulate the disease course are desperately needed. Our objective was to evaluate the efficacy and tolerability of Elysium Health's candidate drug EH301 in people with ALS (PALS).METHODSThis was a single-center, prospective, double-blind, randomized, placebo-controlled pilot study. Thirty-two PALS were recruited thanks to the collaboration of the Spanish Foundation for ALS Research (FUNDELA). Study participants were randomized to receive either EH301 or placebo and underwent evaluation for 4 months. Differences between EH301 and placebo-treated participants were evaluated based on standard clinical endpoints, including the revised ALS functional rating scale (ALSFRS-R), forced vital capacity (FVC), and the Medical Research Council (MRC) grading scale.RESULTSCompared to placebo, participants treated with EH301 demonstrated significant improvements in the ALSFRS-R score, pulmonary function, muscular strength, and in skeletal muscle/fat weight ratio. EH301 was shown to significantly slow the progression of ALS relative to placebo, and even showed improvements in several key outcome measures compared with baseline.CONCLUSIONSThis study provides evidence in support of the disease-modifying effects of EH301 for the treatment of ALS.

100 Deals associated with Nicotinamide riboside/Pterostilbene

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Menopausal syndrome	Phase 2	US	-	30 Mar 2021
Aortic Aneurysm	Phase 2	US	Elysium Health, Inc.Startup	01 Dec 2020
Acute Kidney Injury	Phase 2	US	Elysium Health, Inc.Startup	08 Apr 2020
Amyotrophic Lateral Sclerosis	Phase 2	-	Elysium Health, Inc.Startup	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


HD 11 (ASCO2005)	Not Applicable	Hodgkin's Lymphoma	1,363	ABVDABVDABVDABVD + 30 Gy IF-RT	auhlwqfczx(zcnjemurfd) = Both for FFTF and OS, there was no sequential significant difference either between ABVD and BEACOPP arms nor between 30 Gy and 20 Gy IF-RT arms lqvrqqednb (cdlwkjagrz ) View more	-	01 Jun 2005
				BEACOPP basis + 30 Gy IF-RT